By 2010 Amgen expects to employ more than 1,100 people at its new Irish facility, which will produce products for patients in Europe and other parts of the world.
“Amgen is pleased to establish a site in Ireland as part of our ongoing global development and manufacturing expansion,” said Fabrizio Bonanni, senior vice president, Manufacturing. “As demand for our products grows in Europe, Amgen requires capacity closer to this important market.”
Amgen also announced that it intends to expand its existing R&D operations at sites in the US including Cambridge, Massachusetts, San Francisco and Seattle. Additionally the company plans to add to operations in the UK and build a new development center in Uxbridge, UK.
The company is currently adding a manufacturing plant in Puerto Rico to produce Epogen and Aranesp.